Other Countries
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Quotable: Top Experts On Policy Hot Topics
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
Brazil Issues Guidance On Regulatory Reliance & Equivalent Authorities
Brazilian regulator Anvisa is relying on the decisions of its foreign counterparts as a means of ensuring more quality medicines are made available in the country.
National Real-World Evidence Frameworks For HTA Should Be Consistent, Not Identical
Health technology assessment bodies must strike a fine balance between standardizing their real-world evidence frameworks with those of other countries and tailoring them to meet population-specific needs, an expert tells England’s NICE.
UK, US & Canada Regulators Explain Why Decentralized Trials May Get A Closer Look
Decentralized clinical trials are subject to the same regulatory requirements as traditional site-based trials, but are of special interest to regulators because they represent a new way of working.
US FDA Looks To Re-Establish African Foreign Office, Add Brazil Post
As Congress pressures FDA to increase foreign inspections, the agency unveils plans to strengthen its overseas presence, including new offices and more staff in the New Delhi, India, post. Deputy Commissioner Kimberlee Trzeciak notes the moves are resource dependent.
New UAE Drug Agency Calls On Companies To Help Shape Mandate
Facilitating and strengthening R&D, intellectual property rights protection and drug safety are among the goals of the soon-to-be-launched Emirates Drug Establishment.
Global Pharma Guidance Tracker – February 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Universal Pharmacare Makes Headway In Canada But Pharma Warns It Will Limit Access
Among the provisions in a newly tabled bill seeking to introduce a national pharmacare system in Canada is a bulk purchasing strategy for prescription drugs that could help lower costs.
For Generics, EU Reference Product Is Non-Negotiable – Even In Pilot On Parallel Advice
Acknowledging that it may be a barrier to some extent, EMA’s senior scientific specialist of clinical pharmacology Kevin Blake notes that EU reference medicinal products are a legal requirement for bioequivalence studies and cannot be circumvented.
Mexico Launches ‘Regulatory Certainty Strategy’ For Biosimilars
Mexico is to establish a new regulatory framework that is in line with international standards to encourage domestic production of biosimilar medicines.
Global Pharma Guidance Tracker – January 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Canada Attacks Florida’s ‘Bad’ Bulk Importation Plan
Regulatory tools designed to prevent medicines intended for Canada being diverted elsewhere will be “crucial” for preventing shortages in the country, say Canadian authorities and industry representatives.
EMA Steps Up Support For Creation Of African Medicines Agency
The EU drugs regulator plans to provide the expertise needed to make the African Medicines Agency operational and to help develop the capabilities of the African drug regulatory network.
Regulatory Reliance Pathways: Challenges And Opportunities Ahead
International interest in fast-track regulatory reliance and collaboration pathways such as Project Orbis and the ACCESS Consortium has grown in recent years, a trend that looks set to continue in 2024. But some policy experts have warned that faster approvals are not always better, with one academic claiming the bar for marketing authorizations has dropped “far too low.”
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.